Product Details
Auro-Sunitinib
Sunitinib Malate12.5 mg
Capsule
DIN/PIN/NPN
02532190
Manufacturer
Auro Pharma Inc.
Formulary Listing Date
2023-08-31
Unit Price
55.3553
Amount MOH Pays
55.3553
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L01EX01
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02280795 | Sutent | 65.1240 | 55.3553 |
02524058 | Taro-Sunitinib | 55.3553 | 55.3553 |
02532840 | Sandoz Sunitinib | 55.3553 | 55.3553 |
02532190 | Auro-Sunitinib | 55.3553 | 55.3553 |
02526204 | Teva-Sunitinib | 55.3553 | 55.3553 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Oncology Drugs | Sunitinib
For the treatment of gastrointestinal stromal tumour (GIST) in patients with unresectable or metastatic/recurrent GIST where one of the following conditions is met:
*Definition of intolerance to imatinib – patient has experienced persistent grade 3 toxicity requiring discontinuation of therapy. Duration of Approval: 6 months Renewal will be considered for patients who are stable (no disease progression) and not experiencing intolerance to sunitinib therapy. Note: Approval will be granted at a dose of 50mg per day (4 weeks on, 2 weeks off). For the treatment of metastatic renal cell carcinoma (MRCC):
Duration of Approval: 1 year Renewal will be considered for patients with documentation of radiography and/or scan results indicating no diseases progression. Duration of Approval: 1 year Note: The prescribed dosage should be 50 mg daily for four (4) weeks, followed by two (2) weeks off the Drug Product, in repeated six (6) week cycles. For the treatment of progressive, unresectable, well-differentiated or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (“pNET”) with good performance status (ECOG ≤ 2), until disease progression. Exclusion criteria: Sutent will not be approved for second-line sequential therapy after everolimus failure in the first-line setting. |